Table of Contents
New Journal of Science
Volume 2014 (2014), Article ID 476974, 10 pages
http://dx.doi.org/10.1155/2014/476974
Review Article

Regulations of P-Glycoprotein/ABCB1/MDR1 in Human Cancer Cells

Division of Chemotherapy, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan

Received 9 January 2014; Accepted 25 April 2014; Published 20 May 2014

Academic Editor: Naoki Mori

Copyright © 2014 Kazuhiro Katayama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. J. Goldstein, H. Galski, A. Fojo et al., “Expression of a multidrug resistance gene in human cancers,” Journal of the National Cancer Institute, vol. 81, no. 2, pp. 116–124, 1989. View at Google Scholar · View at Scopus
  2. T. Tsuruo, M. Naito, A. Tomida et al., “Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal,” Cancer Science, vol. 94, no. 1, pp. 15–21, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Kimura, S. Morita, M. Matsuo, and K. Ueda, “Mechanism of multidrug recognition by MDR1/ABCB1,” Cancer Science, vol. 98, no. 9, pp. 1303–1310, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. M. M. Gottesman, C. A. Hrycyna, P. V. Schoenlein, U. A. Germann, and I. Pastan, “Genetic analysis of the multidrug transporter,” Annual Review of Genetics, vol. 29, pp. 607–649, 1995. View at Publisher · View at Google Scholar · View at Scopus
  5. M. M. Gottesman, T. Fojo, and S. E. Bates, “Multidrug resistance in cancer: role of ATP-dependent transporters,” Nature Reviews Cancer, vol. 2, no. 1, pp. 48–58, 2002. View at Google Scholar · View at Scopus
  6. E. M. Leslie, R. G. Deeley, and S. P. Cole, “Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense,” Toxicology and Applied Pharmacology, vol. 204, no. 3, pp. 216–237, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. J.R. Riordan, K. Deuchars, N. Kartner, N. Alon, J. Trent, and V. Ling, “Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines,” Nature, vol. 316, no. 6031, pp. 817–819, 1985. View at Google Scholar · View at Scopus
  8. D.W. Shen, A. Fojo, J.E. Chin et al., “Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification,” Science, vol. 232, no. 4750, pp. 643–645, 1986. View at Google Scholar · View at Scopus
  9. S. Gupta and S. Gollapudi, “P-glycoprotein (MDR 1 gene product) in cells of the immune system: its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection,” Journal of Clinical Immunology, vol. 13, no. 5, pp. 289–301, 1993. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Ludescher, G. Pall, E. U. Irschick, and G. Gastl, “Differential activity of P-glycoprotein in normal blood lymphocyte subsets,” British Journal of Haematology, vol. 101, no. 4, pp. 722–727, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Puddu, S. Fais, F. Luciani et al., “Interferon-γ up-regulates expression and activity of P-glycoprotein in human peripheral blood monocyte-derived macrophages,” Laboratory Investigation, vol. 79, no. 10, pp. 1299–1309, 1999. View at Google Scholar · View at Scopus
  12. N. Kartner, M. Shales, J. R. Riordan, and V. Ling, “Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein,” Cancer Research, vol. 43, no. 9, pp. 4413–4419, 1983. View at Google Scholar · View at Scopus
  13. G. H. Mickisch, L. H. Pai, M. M. Gottesman, and I. Pastan, “Monoclonal antibody MRK16 reverses the multidrug resistance of multidrug- resistant transgenic mice,” Cancer Research, vol. 52, no. 16, pp. 4427–4432, 1992. View at Google Scholar · View at Scopus
  14. H. Hamada and T. Tsuruo, “Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 20, pp. 7785–7789, 1986. View at Google Scholar · View at Scopus
  15. Y. Tanigawara, N. Okamura, M. Hirai et al., “Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1),” The Journal of Pharmacology and Experimental Therapeutics, vol. 263, no. 2, pp. 840–845, 1992. View at Google Scholar · View at Scopus
  16. M. T. Huisman, J. W. Smit, and A. H. Schinkel, “Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors,” AIDS, vol. 14, no. 3, pp. 237–242, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Yamazaki, H. Suzuki, and Y. Sugiyama, “Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics,” Pharmaceutical Research, vol. 13, no. 4, pp. 497–513, 1996. View at Publisher · View at Google Scholar
  18. T. W. Loo and D. M. Clarke, “Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux,” The Journal of Membrane Biology, vol. 206, no. 3, pp. 173–185, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. T. W. Loo and D. M. Clarke, “Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein,” Biochemistry, vol. 33, no. 47, pp. 14049–14057, 1994. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Kajiji, F. Talbot, K. Grizzuti et al., “Functional analysis of P-glycoprotein mutants identifies predicted transmembrane domain 11 as a putative drug binding site,” Biochemistry, vol. 32, no. 16, pp. 4185–4194, 1993. View at Google Scholar · View at Scopus
  21. P. Hafkemeyer, S. Dey, S. V. Ambudkar, C. A. Hrycyna, I. Pastan, and M. M. Gottesman, “Contribution to substrate specificity and transport of nonconserved residues in transmembrane domain 12 of human P-glycoprotein,” Biochemistry, vol. 37, no. 46, pp. 16400–16409, 1998. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Imai, E. Ishikawa, S. Asada, and Y. Sugimoto, “Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2,” Cancer Research, vol. 65, no. 2, pp. 596–604, 2005. View at Google Scholar · View at Scopus
  23. K. Mutoh, S. Tsukahara, J. Mitsuhashi, K. Katayama, and Y. Sugimoto, “Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells,” Cancer Science, vol. 97, no. 11, pp. 1198–1204, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Takada, H. Suzuki, Y. Gotoh, and Y. Sugiyama, “Regulation of the cell surface expression of human BCRP/ABCG2 by the phosphorylation state of Akt in polarized cells,” Drug Metabolism and Disposition, vol. 33, no. 7, pp. 905–909, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Katayama, S. Yoshioka, S. Tsukahara, J. Mitsuhashi, and Y. Sugimoto, “Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein,” Molecular Cancer Therapeutics, vol. 6, no. 7, pp. 2092–2102, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. J. S. Sebolt-Leopold and R. Herrera, “Targeting the mitogen-activated protein kinase cascade to treat cancer,” Nature Reviews Cancer, vol. 4, no. 12, pp. 937–947, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. E. F. Wagner and A. R. Nebreda, “Signal integration by JNK and p38 MAPK pathways in cancer development,” Nature Reviews Cancer, vol. 9, no. 8, pp. 537–549, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Fukuyo, C. R. Hunt, and N. Horikoshi, “Geldanamycin and its anti-cancer activities,” Cancer Letters, vol. 290, no. 1, pp. 24–35, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Lu, Y. Q. Hou, Y. Song, and Z. J. Yuan, “TFPI-2 downregulates multidrug resistance protein in 5-FU-resistant human hepatocellular carcinoma BEL-7402/5-FU cells,” The Anatomical Record, vol. 296, no. 1, pp. 56–63, 2013. View at Publisher · View at Google Scholar
  30. X. Guo, N. Ma, J. Wang et al., “Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells,” BMC cancer, vol. 8, article 375, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Barancik, V. Bohacova, J. Kvackajova, S. Hudecova, O. Krizanova, and A. Breier, “SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance,” European Journal of Pharmaceutical Sciences, vol. 14, no. 1, pp. 29–36, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Liu, R. Aneja, H. Wang et al., “Modulation of multidrug resistance in cancer cells by the E3 ubiquitin ligase seven-in-absentia homologue I,” The Journal of Pathology, vol. 214, no. 4, pp. 508–514, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Bark and C.-H. Choi, “PSC833, cyclosporine analogue, downregulates MDR1 expression by activating JNK/c-Jun/AP-1 and suppressing NF-κB,” Cancer Chemotherapy and Pharmacology, vol. 65, no. 6, pp. 1131–1136, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. Q. Chen, Y. Bian, and S. Zeng, “Involvement of AP-1 and NF-κB in the up-regulation of P-gp in vinblastine resistant Caco-2 cells,” Drug Metabolism and Pharmacokinetics, vol. 29, no. 2, pp. 223–226, 2014. View at Publisher · View at Google Scholar
  35. R. Maitra and J. W. Hamilton, “Arsenite regulates cystic fibrosis transmembrane conductance regulator and P-glycoprotein: evidence of pathway independence,” Cellular Physiology and Biochemistry, vol. 16, no. 1–3, pp. 109–118, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. B. X. Zhao, Y. B. Sun, S. Q. Wang et al., “Grape seed procyanidin reversal of P-glycoprotein associated multi-drug resistance via down-regulation of NF-κB and MAPK/ERK mediated YB-1 activity in A2780/T cells,” PLoS ONE, vol. 8, no. 8, article e71071, 2013. View at Publisher · View at Google Scholar
  37. H. Tomiyasu, M. Watanabe, Y. Goto-Koshino et al., “Regulation of expression of ABCB1 and LRP genes by mitogen-activated protein kinase/extracellular signal-regulated kinase pathway and its role in generation of side population cells in canine lymphoma cell lines,” Leukemia & Lymphoma, vol. 54, no. 6, pp. 1309–1315, 2013. View at Publisher · View at Google Scholar
  38. H. Shen, W. Xu, W. Luo et al., “Upregulation of mdr1 gene is related to activation of the MAPK/ERK signal transduction pathway and YB-1 nuclear translocation in B-cell lymphoma,” Experimental Hematology, vol. 39, no. 5, pp. 558–569, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Gericke, M. Munson, and A. H. Ross, “Regulation of the PTEN phosphatase,” Gene, vol. 374, no. 1-2, pp. 1–9, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Nakagawa, Y. Toyoda, K. Wakabayashi-Nakao, H. Tamaki, M. Osumi, and T. Ishikawa, “Ubiquitin-mediated proteasomal degradation of ABC transporters: a new aspect of genetic polymorphisms and clinical impacts,” Journal of Pharmaceutical Sciences, vol. 100, no. 9, pp. 3602–3619, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Wakabayashi-Nakao, A. Tamura, T. Furukawa, H. Nakagawa, and T. Ishikawa, “Quality control of human ABCG2 protein in the endoplasmic reticulum: ubiquitination and proteasomal degradation,” Advanced Drug Delivery Reviews, vol. 61, no. 1, pp. 66–72, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. E. L. Turnbull, M. F. Rosser, and D. M. Cyr, “The role of the UPS in cystic fibrosis,” BMC Biochemistry, vol. 8, no. 1, article S11, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. J. M. Younger, H.-Y. Ren, L. Chen et al., “A foldable CFTRΔF508 biogenic intermediate accumulates upon inhibition of the Hsc70-CHIP E3 ubiquitin ligase,” The Journal of Cell Biology, vol. 167, no. 6, pp. 1075–1085, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. G. C. Meacham, C. Patterson, W. Zhang, J. M. Younger, and D. M. Cyr, “The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation,” Nature Cell Biology, vol. 3, no. 1, pp. 100–105, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. Y. Yoshida, T. Chiba, F. Tokunaga et al., “E3 ubiquitin ligase that recognizes sugar chains,” Nature, vol. 418, no. 6896, pp. 438–442, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Katayama, K. Noguchi, and Y. Sugimoto, “FBXO15 regulates P-glycoprotein/ABCB1 expression through the ubiquitin-proteasome pathway in cancer cells,” Cancer Science, vol. 104, no. 6, pp. 694–702, 2013. View at Publisher · View at Google Scholar
  47. H. Zhu, H. Wu, X. Liu et al., “Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells,” Biochemical Pharmacology, vol. 76, no. 5, pp. 582–588, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. O. Kovalchuk, J. Filkowski, J. Meservy et al., “Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin,” Molecular Cancer Therapeutics, vol. 7, no. 7, pp. 2152–2159, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. N. Bitarte, E. Bandres, V. Boni et al., “MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells,” Stem Cells, vol. 29, no. 11, pp. 1661–1671, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. D.-D. Feng, H. Zhang, P. Zhang et al., “Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia,” Journal of Cellular and Molecular Medicine, vol. 15, no. 10, pp. 2164–2175, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. Z. Chen, T. Ma, C. Huang et al., “MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells,” Cellular Signalling, vol. 25, no. 12, pp. 2693–2701, 2013. View at Publisher · View at Google Scholar
  52. Z. Li, S. Hu, J. Wang et al., “MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells,” Gynecologic Oncology, vol. 119, no. 1, pp. 125–130, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. Y. Shang, Z. Zhang, Z. Liu et al., “miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1,” Oncogene, 2013. View at Publisher · View at Google Scholar
  54. L. Bao, S. Hazari, S. Mehra, D. Kaushal, K. Moroz, and S. Dash, “Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298,” The American Journal of Pathology, vol. 180, no. 6, pp. 2490–2503, 2012. View at Publisher · View at Google Scholar
  55. K. Ikemura, M. Yamamoto, S. Miyazaki, H. Mizutani, T. Iwamoto, and M. Okuda, “MicroRNA-145 post-transcriptionally regulates the expression and function of P-glycoprotein in intestinal epithelial cells,” Molecular Pharmacology, vol. 83, no. 2, pp. 399–405, 2013. View at Publisher · View at Google Scholar
  56. X. Zhu, Y. Li, H. Shen et al., “miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1,” Acta Biochimica et Biophysica Sinica, vol. 45, no. 2, pp. 80–86, 2013. View at Publisher · View at Google Scholar
  57. J. Chen, W. Tian, H. Cai, H. He, and Y. Deng, “Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer,” Medical Oncology, vol. 29, no. 4, pp. 2527–2534, 2012. View at Publisher · View at Google Scholar
  58. Y. Xu, F. Xia, L. Ma et al., “MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest,” Cancer Letters, vol. 310, no. 2, pp. 160–169, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. X. Zhao, L. Yang, J. Hu, and J. Ruan, “miR-138 might reverse multidrug resistance of leukemia cells,” Leukemia Research, vol. 34, no. 8, pp. 1078–1082, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. L. Yang, N. Li, H. Wang, X. Jia, X. Wang, and J. Luo, “Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,” Oncology Reports, vol. 28, no. 2, pp. 592–600, 2012. View at Publisher · View at Google Scholar
  61. F. Wang, T. Li, B. Zhang et al., “MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN,” Biochemical and Biophysical Research Communications, vol. 434, no. 3, pp. 688–694, 2013. View at Publisher · View at Google Scholar
  62. M. Hochstrasser, “Origin and function of ubiquitin-like proteins,” Nature, vol. 458, no. 7237, pp. 422–429, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. G. Nalepa, M. Rolfe, and J. W. Harper, “Drug discovery in the ubiquitin—proteasome system,” Nature Reviews Drug Discovery, vol. 5, no. 7, pp. 596–613, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. D. Hoeller, C.-M. Hecker, and I. Dikic, “Ubiquitin and ubiquitin-like proteins in cancer pathogenesis,” Nature Reviews Cancer, vol. 6, no. 10, pp. 776–788, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. D. Hoeller and I. Dikic, “Targeting the ubiquitin system in cancer therapy,” Nature, vol. 458, no. 7237, pp. 438–444, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. J. Jin, T. Cardozo, R. C. Lovering, S. J. Elledge, M. Pagano, and J. W. Harper, “Systematic analysis and nomenclature of mammalian F-box proteins,” Genes & Development, vol. 18, no. 21, pp. 2573–2580, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. J. T. Winston, D. M. Koepp, Z. Cihui, S. J. Elledge, and J. W. Harper, “A family of mammalian F-box proteins,” Current Biology, vol. 9, no. 20, pp. 1180–1182, 1999. View at Publisher · View at Google Scholar · View at Scopus
  68. Y. Tokuzawa, E. Kaiho, M. Maruyama et al., “Fbx15 is a novel target of Oct3/4 but is dispensable for embryonic stem cell self-renewal and mouse development,” Molecular and Cellular Biology, vol. 23, no. 8, pp. 2699–2708, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. C. M. Fader and M. I. Colombo, “Autophagy and multivesicular bodies: two closely related partners,” Cell Death and Differentiation, vol. 16, no. 1, pp. 70–78, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. E.-L. Eskelinen, “New insights into the mechanisms of macroautophagy in mammalian cells,” International Review of Cell and Molecular Biology, vol. 266, pp. 207–247, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Swiatecka-Urban, A. Brown, S. Moreau-Marquis et al., “The short apical membrane half-life of rescued ΔF508-cystic fibrosis transmembrane conductance regulator (CFTR) results from accelerated endocytosis of ΔF508H-CFTR in polarized human airway epithelial cells,” The Journal of Biological Chemistry, vol. 280, no. 44, pp. 36762–36772, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. D. Fu, “Where is it and how does it get there—intracellular localization and traffic of P-glycoprotein,” Frontiers in Oncology, vol. 3, article 321, 2013. View at Publisher · View at Google Scholar
  73. C. Ferrandiz-Huertas, A. Fernandez-Carvajal, and A. Ferrer-Montiel, “Rab4 interacts with the human P-glycoprotein and modulates its surface expression in multidrug resistant K562 cells,” International Journal of Cancer, vol. 128, no. 1, pp. 192–205, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. D. Fu, E. M. van Dam, A. Brymora, I. G. Duggin, P. J. Robinson, and B. D. Roufogalis, “The small GTPases Rab5 and RalA regulate intracellular traffic of P-glycoprotein,” Biochimica et Biophysica Acta, vol. 1773, no. 7, pp. 1062–1072, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. H. Kim, M. Barroso, R. Samanta, L. Greenberger, and E. Sztul, “Experimentally induced changes in the endocytic traffic of P-glycoprotein alter drug resistance of cancer cells,” American Journal of Physiology: Cell physiology, vol. 273, no. 2, part 1, pp. C687–C702, 1997. View at Google Scholar
  76. C. Alemán, J.-P. Annereau, X.-J. Liang et al., “P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential,” Cancer Research, vol. 63, no. 12, pp. 3084–3091, 2003. View at Google Scholar · View at Scopus
  77. K.-V. Chin, S. Tanaka, G. Darlington, I. Pastan, and M. M. Gottesman, “Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells,” The Journal of Biological Chemistry, vol. 265, no. 1, pp. 221–226, 1990. View at Google Scholar · View at Scopus
  78. L. A. Mickley, S. E. Bates, N. D. Richert et al., “Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents,” The Journal of Biological Chemistry, vol. 264, no. 30, pp. 18031–18040, 1989. View at Google Scholar · View at Scopus
  79. N. D. Richert, L. Aldwin, D. Nitecki, M. M. Gottesman, and I. Pastan, “Stability and covalent modification of P-glycoprotein in multidrug-resistant KB cells,” Biochemistry, vol. 27, no. 20, pp. 7607–7613, 1988. View at Google Scholar · View at Scopus
  80. H.T. Cuypers, G. Selte, W. Quint et al., “Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region,” Cell, vol. 37, no. 1, pp. 141–150, 1984. View at Google Scholar · View at Scopus
  81. G. Selten, H. T. Cuypers, and A. Berns, “Proviral activation of the putative oncogene Pim-1 in MuLV induced T-cell lymphomas,” The EMBO Journal, vol. 4, no. 7, pp. 1793–1798, 1985. View at Google Scholar · View at Scopus
  82. M. Bachmann and T. Möröy, “The serine/threonine kinase Pim-1,” The International Journal of Biochemistry & Cell Biology, vol. 37, no. 4, pp. 726–730, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. Y. Xie, M. Burcu, D. E. Linn, Y. Qiu, and M. R. Baer, “Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression,” Molecular Pharmacology, vol. 78, no. 2, pp. 310–318, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. Y. Xie, K. Xu, D. E. Linn et al., “The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells,” The Journal of Biological Chemistry, vol. 283, no. 6, pp. 3349–3356, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. T. C. Chambers, J. Pohl, D. B. Glass, and J. F. Kuo, “Phosphorylation by protein kinase C and cyclic AMP-dependent protein kinase of synthetic peptides derived from the linker region of human P-glycoprotein,” The Biochemical Journal, vol. 299, no. 1, pp. 309–315, 1994. View at Google Scholar · View at Scopus
  86. U. A. Germann, T. C. Chambers, S. V. Ambudkar et al., “Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells,” The Journal of Biological Chemistry, vol. 271, pp. 1708–1716, 1996. View at Google Scholar
  87. K. A. Wojtal, E. de Vries, D. Hoekstra, and S. C. D. van Ijzendoorn, “Efficient trafficking of MDR1/P-glycoprotein to apical canalicular plasma membranes in HepG2 cells requires PKA-RIIα anchoring and glucosylceramide,” Molecular Biology of the Cell, vol. 17, no. 8, pp. 3638–3650, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. S. M. Mattaloni, E. Kolobova, C. Favre, R. A. Marinelli, J. R. Goldenring, and M. C. Larocca, “AKAP350 Is involved in the development of apical “Canalicular” structures in hepatic cells HepG2,” Journal of Cellular Physiology, vol. 227, no. 1, pp. 160–171, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. J. J. Michel and J. D. Scott, “AKAP mediated signal transduction,” Annual Review of Pharmacology and Toxicology, vol. 42, pp. 235–257, 2002. View at Publisher · View at Google Scholar · View at Scopus
  90. S. S. Taylor, P. Zhang, J. M. Steichen, M. M. Keshwani, and A. P. Kornev, “PKA: lessons learned after twenty years,” Biochimica et Biophysica Acta, vol. 1834, no. 7, pp. 1271–1278, 2013. View at Publisher · View at Google Scholar
  91. M. E. Cvijic and K. V. Chin, “Regulation of P-glycoprotein expression in cyclic AMP-dependent protein kinase mutants,” Cell Growth & Differentiation, vol. 8, no. 12, pp. 1243–1247, 1997. View at Google Scholar
  92. G. Zhou and M. T. Kuo, “NF-κB-mediated induction of mdr1b expression by insulin in rat hepatoma cells,” The Journal of Biological Chemistry, vol. 272, no. 24, pp. 15174–15183, 1997. View at Google Scholar
  93. F. Thévenod, J. M. Friedmann, A. D. Katsen, and I. A. Hauser, “Up-regulation of multidrug resistance P-glycoprotein via nuclear factor- κB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis,” The Journal of Biological Chemistry, vol. 275, no. 3, pp. 1887–1896, 2000. View at Publisher · View at Google Scholar · View at Scopus
  94. R. Kanagasabai, K. Krishnamurthy, L. J. Druhan, and G. Ilangovan, “Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in adriamycin-resistant human breast cancer cells,” The Journal of Biological Chemistry, vol. 286, no. 38, pp. 33289–33300, 2011. View at Publisher · View at Google Scholar · View at Scopus
  95. C. Murga, M. Zohar, H. Teramoto, and J. S. Gutkind, “Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF-κB,” Oncogene, vol. 21, no. 2, pp. 207–216, 2002. View at Publisher · View at Google Scholar · View at Scopus
  96. M. T. Kuo, Z. Liu, Y. Wei et al., “Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-κB signaling,” Oncogene, vol. 21, no. 13, pp. 1945–1954, 2002. View at Publisher · View at Google Scholar · View at Scopus
  97. K. Katayama, A. Nakamura, Y. Sugimoto, T. Tsuruo, and N. Fujita, “FOXO transcription factor-dependent p15INK4b and p19INK4d expression,” Oncogene, vol. 27, no. 12, pp. 1677–1686, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. C.-Y. Han, K.-B. Cho, H.-S. Choi, H.-K. Han, and K.-W. Kang, “Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells,” Carcinogenesis, vol. 29, no. 9, pp. 1837–1844, 2008. View at Publisher · View at Google Scholar · View at Scopus
  99. W. K. Oh, K. B. Cho, T. T. Hien et al., “Amurensin G, a potent natural SIRT1 inhibitor, rescues doxorubicin responsiveness via down-regulation of multidrug resistance 1,” Molecular Pharmacology, vol. 78, no. 5, pp. 855–864, 2010. View at Publisher · View at Google Scholar · View at Scopus
  100. R. C. Hui, R. E. Francis, S. K. Guest et al., “Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells,” Molecular Cancer Therapeutics, vol. 7, no. 3, pp. 670–678, 2008. View at Publisher · View at Google Scholar · View at Scopus
  101. F. Thévenod and P. K. Chakraborty, “The role of wnt/beta-catenin signaling in renal carcinogenesis: lessons from cadmium toxicity studies,” Current Molecular Medicine, vol. 10, no. 4, pp. 387–404, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. J. C. Lim, K. D. Kania, H. Wijesuriya et al., “Activation of β-catenin signalling by GSK-3 inhibition increases P-glycoprotein expression in brain endothelial cells,” Journal of Neurochemistry, vol. 106, no. 4, pp. 1855–1865, 2008. View at Publisher · View at Google Scholar · View at Scopus
  103. S. Corrêa, R. Binato, B. Du Rocher, M. T. Castelo-Branco, L. Pizzatti, and E. Abdelhay, “Wnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia,” BMC Cnacer, vol. 12, article 303, 2012. View at Publisher · View at Google Scholar
  104. V. Lopes-Rodrigues, H. Seca, D. Sousa, E. Sousa, R. T. Lima, and M. H. Vasconcelos, “The network of P-glycoprotein and microRNAs interactions,” International Journal of Cancer, 2013. View at Publisher · View at Google Scholar